Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
REDWOOD CITY, Calif., May 03, 2017 -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2017 financial results on Monday, May 8th, 2017. OncoMed management will host a conference call and webcast to review 2017 first-quarter financial results and provide a corporate update at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by dialing 1-855-420-0692 (domestic) and 1-484-756-4194 (international) using the conference ID# 18252865. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com, and will be available for replay through August 31, 2017.
An audio replay of the conference call can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) utilizing the conference ID number listed above.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer/ immuno-oncology therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. Demcizumab (anti-DLL4, OMP-21M18), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company’s strategic alliances with Celgene Corporation. OncoMed is independently developing vantictumab (anti-Fzd, OMP-18R5), ipafricept (Fzd8-Fc, OMP-54F28) and GITRL-Fc (OMP-336B11), as well as continuing to pursue new immuno-oncology drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact Peter Rahmer Trout Group [email protected] (646) 378-2973 Mike Zanoni Trout Group [email protected] (646) 378-2924
